Neostigmine is used to treat myasthenia gravis, a condition where muscles become weak and tired easily, and to reverse the effects of certain anesthesia drugs after surgery.[1] Prostigmin is currently being investigated across 11 indications[3], with its most advanced program in Phase 3.[1]
Prostigmin is one of 182 small molecule programs targeting Arrhythmia. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
95 competitors in Liver Transplant
Prostigmin
Giapreza
Prothrombin Complex Concentrate
Darbepoetin
Tacrolimus Pill
Lenvima
Octreotide
Beyfortus
Myfortic
Cyklokapron
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details